Evaluation of serum mid-infrared spectroscopy as new prognostic marker for first-line bevacizumab-based chemotherapy in metastatic colorectal cancer
Year: 2024
Type: article
Abstract: BACKGROUND AND AIMS: Bevacizumab-based chemotherapy is a recommended first-line treatment for metastatic colorectal cancer (mCRC). Robust biomarkers with clinical practice applicability have not been identified for patients with this treatment. We aimed to evaluate the prognostic yield of serum mid-infrared spectroscopy (MIRS) on patients receiving first-line bevacizumab-based chemotherapy for mCRC. METHODS: We conducted an ancillary analysis from a multicentre prospective study (NCT00489697). All baseline serums were screened by attenuated total reflection method. Principal component analysis and unsupervised k-mean partitioning methods were performed blinded to all patients' data. Endpoints were progression-free survival (PFS) and overall survival (OS). RESULTS: From the 108 included patients, MIRS discriminated two prognostic groups. First group patients had significantly lower body mass index (p = 0.026) and albumin levels (p < 0.001), and higher levels of angiogenic markers, lactate dehydrogenase and carcinoembryonic antigen (p < 0.001). In univariate analysis, their OS and PFS were shorter with respective medians: 17.6 vs 27.9 months (p = 0.02) and 8.7 vs 11.3 months (p = 0.03). In multivariate analysis, PFS was significantly shorter (HR = 1.74, p = 0.025) with a similar trend for OS (HR = 1.69, p = 0.061). CONCLUSION: By metabolomic fingerprinting, MIRS proves to be a promising prognostic tool for patients receiving first-line bevacizumab-based chemotherapy for mCRC.
Source: Digestive and Liver Disease
Institutions: Université de Tours, Inserm, Centre Hospitalier Universitaire de Tours, Niche, Nutrition, Cancer et métabolisme oxydatif, Centre Hospitalier Universitaire de Reims, Centre Hospitalier Universitaire de Besançon, Université de Bourgogne, CHU Dijon Bourgogne, Centre de recherche Translationnelle en Médecine moléculaire, Institut de Cancérologie de l'Ouest, Sorbonne Université, Assistance Publique – Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Centre National de la Recherche Scientifique, Niche leucémique et métabolisme oxydatif, Centre Hospitalier Universitaire de Poitiers, Institut Gustave Roussy, Prédicteurs moléculaires et nouvelles cibles en oncologie, Université de Bretagne Sud, Institut de Recherche Dupuy de Lôme
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,300
Funders: Agence Nationale de la Recherche, Institut National de la Santé et de la Recherche Médicale, Ministère de l'Enseignement Supérieur et de la Recherche, Institut National Du Cancer, Société Nationale Française de Gastro-Entérologie, Centre Hospitalier Universitaire de Bordeaux, Ministère de l'Enseignement supérieur, de la Recherche et de l'Innovation, Centre Hospitalier Universitaire de Poitiers, Department of Radiology, Weill Cornell Medical College
OpenAlex ID: W4401690414